"Zepbound: Promising Treatment for Obstructive Sleep Apnea Trials"
TL;DR Summary
Eli Lilly's obesity drug Zepbound has shown positive results in treating obstructive sleep apnea (OSA) in a Phase 3 study, potentially positioning it as the first approved treatment for OSA. Patients taking Zepbound experienced a significant reduction in the apnea-hypopnea index compared to those on a placebo, indicating its potential to address breathing interruptions during sleep in individuals with obesity.
- Zepbound effective in obstructive sleep apnea trials - STAT STAT
- Weight loss drug Zepbound may help people with obstructive sleep apnea, drugmaker says CNN
- Eli Lilly drug Zepbound: Will it help my obstructive sleep apnea? Fast Company
- ASML Stock Dives. Chip Makers Are Cautious. Barron's
- Zepbound, Eli Lilly obesity drug, promising treatment for sleep apnea USA TODAY
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
1 min
vs 1 min read
Condensed
64%
167 → 60 words
Want the full story? Read the original article
Read on STAT